CoII/Box‐catalyzed [Box=bis(oxazoline)] enantioselective addition of potassium allyltrifluoroborate to cyclic ketimines was developed, providing the corresponding chiral α‐tertiary amines in high yields and with good enantioselectivity values. Alkoxycarbonyl‐ and alkyl‐substituted saccharin‐derived ketimines are suitable substrates for this allylation reaction. The product can be converted to complex molecules
开发了Co II / Box催化的[Box =双(恶唑啉)]烯丙基三氟硼酸钾对环酮亚胺的对映选择性加成,提供了高收率和良好对映选择性值的相应手性α-叔胺。烷氧羰基和烷基取代的糖精衍生的酮亚胺是该烯丙基化反应的合适底物。该产品可以通过几个简单的步骤转化为复杂的分子,包括MK-0371的前体,它是一种驱动蛋白纺锤体蛋白抑制剂。另外,该催化体系显示出强烈的正非线性效应。
Copper-catalyzed asymmetric alkynylation of cyclic N-sulfonyl ketimines
cyclic N-sulfonyl ketimines was developed, providing the corresponding chiral α-tertiary amines with up to 98% ee. The method tolerates some variations in cyclic N-sulfonyl ketimine and alkyne scope. These products could be used in several transformations, in particular, the products of 6-membered cyclic N-sulfonyl ketimines could be easily converted to linear chiral α-tertiary amines. This asymmetric
Herbicidal Compounds Based on N-Azinyl-N-Phenylsulfonylureas
申请人:Rosinger Christoph Hugh
公开号:US20110105324A1
公开(公告)日:2011-05-05
What is described are compounds of the formula (I)
in which the respective substituents have the meanings given in the description. The compounds of the formula (I) can be used as herbicides and plant growth regulators.
Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.
[EN] BIS(SULFONAMIDE) DERIVATIVES AND THEIR USE AS MPGES INHIBITORS<br/>[FR] DÉRIVÉS DE BIS (SULFONAMIDE) ET LEUR UTILISATION COMME INHIBITEURS DE MPGES
申请人:ACTURUM LIFE SCIENCE AB
公开号:WO2016085392A1
公开(公告)日:2016-06-02
The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for the treatment and/or prevention of a disease, disorder or condition in which modulation of microsomal prostaglandin E synthase-1 activity is beneficial, such as pain, inflammation and cancer.